SUPERNUS PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.84 USD | -1.57% |
|
-3.75% | +16.93% |
| 09-04 | Transcript : Supernus Pharmaceuticals, Inc. Presents at Wells Fargo 2024 Healthcare Conference, Sep-04-2024 04:30 PM | |
| 08-19 | Sector Update: Health Care Stocks Edge Higher Premarket Monday | MT |
Summary: Supernus Pharmaceuticals, Inc.
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- The company presents an interesting fundamental situation from a short-term investment perspective.
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Highlights: Supernus Pharmaceuticals, Inc.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses: Supernus Pharmaceuticals, Inc.
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company has insufficient levels of profitability.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Ratings Chart: Supernus Pharmaceuticals, Inc.
Source: Surperformance
ESG chart: Supernus Pharmaceuticals, Inc.
Source: Refinitiv
| Composite Fundamentals | Composite Valuation | Composite Momentum | Capi. ($) | ||
|---|---|---|---|---|---|
| - | 1.86B | ||||
| 81.49B | |||||
| 11.86B | |||||
| 7.12B | |||||
| 6.12B | |||||
| 2.2B | |||||
| 1.98B | |||||
| - | 1.94B | ||||
| 1.37B | |||||
| Average | 12.88B | ||||
| Weighted average by Cap. |
Investor Rating
Trading Rating
ESG Refinitiv
D+
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- SUPN Stock
- Ratings Supernus Pharmaceuticals, Inc.
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition